A Study to Evaluate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Xdivane versus Opdivo® in Patients with Resected Melanoma

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522307-14-00

Acronym

0439-24

Enrollment

Registered

2025-12-08

Start date

2026-01-19

Completion date

Unknown

Last updated

2025-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melanoma

None listed

Sex/Gender

All

Age

18 Years to No maximum

Romania, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026